Report from a case series found that targeting BAFF with a BAFF receptor inhibitor (belimumab) did not benefit patients with PBC; it could normalize the IgM levels but not alleviate the liver inflammation in patients with PBC (25). Here, CD40LG is linked to primary biliary cholangitis.